Axsome Therapeutics Inc. Common Stock (AXSM)
Stock · NASDAQ · Health Care
$157.09as of 10/16/2026
Price chart
Active signals
AXSM Signal Track Record
How signals performed across all stocks →What AXSM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +3.4% | 62% | September 29, 2026 |
| Bollinger Band Breakout | 27 | +1.1% | 63% | September 11, 2026 |
| Bollinger Band Breakdown | 16 | -1.5% | 44% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +11.6% | 69% | August 7, 2025 |
| Any 20-session window (baseline) | +1.6% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,346
- Website
- www.axsome.com/
Fundamentals
- 1-day range
- $156.09$160.43
- Market cap
- $10.81B
- P/E (trailing)
- —
- P/E (forward)
- 38.91
- EPS (trailing)
- $-3.76
- Dividend yield
- —
- Beta
- 0.80
- Avg. volume
- 727.4K
How Axsome Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Axsome Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayYahoo · 10/9/2026
- RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295benzinga · 10/8/2026
- RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295Benzinga · 10/8/2026
- Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?Yahoo · 10/8/2026
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2Yahoo · 10/7/2026
- Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)Yahoo · 10/5/2026
- Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Yahoo · 10/1/2026
- Jefferies Highlights Three Biotech Stocks With Blockbuster PotentialYahoo · 9/30/2026
- Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267Benzinga · 9/29/2026
Insider Activity
Insider Actions →- Mark L. Jacobson · September 3, 2026 · Option Exercise10.0K @ $12.95
- Mark L. Jacobson · September 3, 2026 · Sale10.0K @ $208.65
- Herriot Tabuteau · August 6, 2026 · Option Exercise4.7K @ $4.95
- Herriot Tabuteau · August 6, 2026 · Sale4.7K @ $213.95
- Herriot Tabuteau · August 5, 2026 · Option Exercise45.0K @ $4.95
- Herriot Tabuteau · August 5, 2026 · Sale45.0K @ $212.01
- Herriot Tabuteau · July 1, 2026 · Option Exercise49.7K @ $4.95
- Herriot Tabuteau · July 1, 2026 · Sale49.7K @ $240.25
- Roger Jeffs · June 11, 2026 · Sale286 @ $249.12
- Roger Jeffs · June 10, 2026 · Sale286 @ $246.18
- Mark Coleman · June 10, 2026 · Sale643 @ $249
- Susan Mahony · June 10, 2026 · Sale300 @ $246.18
- Susan Mahony · June 9, 2026 · Sale300 @ $237.21
- Nick Pizzie · June 9, 2026 · Option Exercise33.0K @ $3.5
- Nick Pizzie · June 9, 2026 · Sale33.0K @ $240.09
Institutional Ownership
March 31, 2026
- Total shares held
- 36.55M
- Total value held
- $5.90B
- Institutional holders
- 403
- Unknown3.91M
- Unknown1.94M
- Unknown1.57M
- Unknown1.32M
- Unknown1.30M
- Unknown1.16M
- Unknown1.15M
- Unknown1.10M
- Unknown986.8K
- Unknown866.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Deutsche Bank cuts Axsome Therapeutics price target to $267
Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.
Deutsche Bank cuts Axsome Therapeutics price target to $267. Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.